Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 10Unknown 4Terminated 3Recruiting 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

UNKNOWN 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Pancreatic Neoplasms 23Breast Neoplasms 19Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Triple Negative Breast Neoplasms 8Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Hodgkin Disease 4Breast Neoplasms, Male 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Urinary Bladder Neoplasms 2Recurrence 2Prostatic Neoplasms 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Pancreatic Ductal 2Carcinoma 2Uterine Cervical Neoplasms 1Thrombocytosis 1Stages II-III Breast Cancer 1Spinal Cord Compression 1Rectal Neoplasms 1

Interventions

Capecitabine 27pembrolizumab 19Oxaliplatin 19Fluorouracil 17Cisplatin 17Trastuzumab 14Docetaxel 14Leucovorin 11Paclitaxel 8Irinotecan 8S 1 (combination) 7Epirubicin 6Cyclophosphamide 5tegafur-gimeracil-oteracil 4aldesleukin 4Hyperthermic Intraperitoneal Chemotherapy 4titanium silicide 3spartalizumab 3fludarabine phosphate 3fludarabine 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Ramucirumab 3Nivolumab 3Indocyanine Green 3Gemcitabine 3Carboplatin 3Albumin-Bound Paclitaxel 3Ado-Trastuzumab Emtansine 3vistusertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Stomach Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT04294784 2024-11-04

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Huazhong University of Science and Technology

Phase 2 Terminated
58 enrolled
Gastrointestinal

Stomach Neoplasms

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01980810 2016-06-14

GC-A-003

ChineseAMS

Phase 2 Terminated
36 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡